$1.68 Billion is the total value of Sofinnova Investments, Inc.'s 69 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AZN | New | AstraZeneca PLCadr | $42,122,000 | – | 842,600 | +100.0% | 2.51% | – |
| XLV | New | Health Care Select Sector SPDRput | $34,032,000 | – | 300,000 | +100.0% | 2.03% | – |
| New | Nextcure, Inc | $29,123,000 | – | 2,671,856 | +100.0% | 1.73% | – | |
| IWM | New | iShares Russell 2000 ETFput | $25,488,000 | – | 130,000 | +100.0% | 1.52% | – |
| HZNP | New | Horizon Therapeutics PLC | $15,609,000 | – | 213,390 | +100.0% | 0.93% | – |
| New | Protagonist Therapeutics Inc | $14,614,000 | – | 724,904 | +100.0% | 0.87% | – | |
| MGNX | New | MacroGenics Inc | $10,488,000 | – | 458,807 | +100.0% | 0.62% | – |
| SRPT | New | Sarepta Therapeutics Inc | $8,840,000 | – | 51,848 | +100.0% | 0.53% | – |
| SNDX | New | Syndax Pharmaceuticals Inc | $8,293,000 | – | 372,909 | +100.0% | 0.49% | – |
| JNCE | New | Jounce Therapeutics Inc | $6,477,000 | – | 925,280 | +100.0% | 0.39% | – |
| ALGS | New | Aligos Therapeutics Inc | $5,283,000 | – | 191,061 | +100.0% | 0.31% | – |
| RCUS | New | Arcus Biosciences Inc | $4,836,000 | – | 186,278 | +100.0% | 0.29% | – |
| IOVA | New | Iovance Biotherapeutics Incput | $4,640,000 | – | 100,000 | +100.0% | 0.28% | – |
| New | Aptose Biosciences Inc | $4,297,000 | – | 981,135 | +100.0% | 0.26% | – | |
| IGMS | New | IGM Biosciences Inc | $3,985,000 | – | 45,131 | +100.0% | 0.24% | – |
| New | Marinus Pharmaceuticals Inc | $3,343,000 | – | 274,027 | +100.0% | 0.20% | – | |
| CALA | New | Calithera Biosciences Incput | $1,964,000 | – | 400,000 | +100.0% | 0.12% | – |
| ZGNX | New | Zogenix Inc | $1,791,000 | – | 89,579 | +100.0% | 0.11% | – |
| CALA | New | Calithera Biosciences Inccall | $860,000 | – | 175,000 | +100.0% | 0.05% | – |
| REPL | New | Replimune Group Inc | $763,000 | – | 20,000 | +100.0% | 0.04% | – |
| BCAB | New | Bioatla Inc | $102,000 | – | 3,000 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.